The p38-mediated rapid down-regulation of cell surface gp130 expression impairs interleukin-6 signaling in the synovial fluid of juvenile idiopathic arthritis patients

Arthritis and Rheumatology

Volumn 66, Issue 2, 2014, Pages 470-478

  Honke, Nora ^a   Ohl, Kim ^a   Wiener, Anastasia ^a   Bierwagen, Jeff ^a   Peitz, Joachim ^b   Di Fiore, Stefano ^c   Fischer, Rainer ^c   Wagner, Norbert ^a   Wüller, Stefan ^a   Tenbrock, Klaus ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GLYCOPROTEIN GP 130; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ARTICLE; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; JUVENILE RHEUMATOID ARTHRITIS; MONOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SYNOVIAL FLUID; WESTERN BLOTTING;

ADOLESCENT; ARTHRITIS, JUVENILE; CELLS, CULTURED; CHILD; CYTOKINE RECEPTOR GP130; DOWN-REGULATION; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; MONOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; SERINE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; SYNOVIAL FLUID;

EID: 84896304574     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38245     Document Type: Article

References (43)

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007; 369: 767-78.
2. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 2011;377: 2138-49.
3. Kutukculer N, Caglayan S, Aydogdu F. Study of pro-inflammatory (TNF-, IL-1-, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters. Clin Rheumatol 1998;17: 288-92.
4. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7: 429-42.
5. De Jager W, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 2007;66: 589-98.
6. published erratum appears in Ann Rheum Dis 2008;67:280
7. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374: 1-20.
8. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997;387: 917-21.
9. Ahmed ST, Ivashkiv LB. Inhibition of IL-6 and IL-10 signaling and Stat activation by inflammatory and stress pathways. J Immunol 2000;165: 5227-37.
10. Kiu H, Hilton DJ, Nicola NA, Ernst M, Marquez R, Alexander WS, et al. Mechanism of crosstalk inhibition of IL-6 signaling in response to LPS and TNF-. Growth Factors 2007;25: 319-28.
11. Radtke S, Wuller S, Yang XP, Lippok BE, Mutze B, Mais C, et al. Cross-regulation of cytokine signalling: pro-inflammatory cytokines restrict IL-6 signalling through receptor internalisation and degradation. J Cell Sci 2010;123: 947-59.
12. Oberg HH, Wesch D, Grussel S, Rose-John S, Kabelitz D. Differential expression of CD126 and CD130 mediates different STAT-3 phosphorylation in CD4-CD25- and CD25high regulatory T cells. Int Immunol 2006;18: 555-63.
13. Walter GJ, Evans HG, Menon B, Gullick NJ, Kirkham BW, Cope AP, et al. Interaction with activated monocytes enhances cytokine expression and suppressive activity of human CD4-CD45RO- CD25-CD127low regulatory T cells. Arthritis Rheum 2013;65: 627-38.
14. Van Amelsfort JM, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS. CD4-CD25- regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum 2004;50: 2775-85.
15. Massey HM, Flanagan AM. Human osteoclasts derive from CD14- positive monocytes. Br J Haematol 1999;106: 167-70.
16. Mulherin D, FitzGerald O, Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1996;39: 115-24.
17. Li J, Hsu HC, Mountz JD. Managing macrophages in rheumatoid arthritis by reform or removal. Curr Rheumatol Rep 2012;14: 445-54.
18. Repnik U, Knezevic M, Jeras M. Simple and cost-effective isolation of monocytes from buffy coats. J Immunol Methods 2003;278: 283-92.
19. Deon D, Ahmed S, Tai K, Scaletta N, Herrero C, Lee IH, et al. Cross-talk between IL-1 and IL-6 signaling pathways in rheumatoid arthritis synovial fibroblasts. J Immunol 2001;167: 5395-403.
20. Thiel S, Dahmen H, Martens A, Muller-Newen G, Schaper F, Heinrich PC, et al. Constitutive internalization and association with adaptor protein-2 of the interleukin-6 signal transducer gp130. FEBS Lett 1998;441: 231-4.
21. Ehlting C, Lai WS, Schaper F, Brenndorfer ED, Matthes RJ, Heinrich PC, et al. Regulation of suppressor of cytokine signaling 3 (SOCS3) mRNA stability by TNF - involves activation of the MKK6/p38MAPK/MK2 cascade. J Immunol 2007;178: 2813-26.
22. Yang XP, Albrecht U, Zakowski V, Sobota RM, Haussinger D, Heinrich PC, et al. Dual function of interleukin-1- for the regulation of interleukin-6-induced suppressor of cytokine signaling 3 expression. J Biol Chem 2004;279: 45279-89.
23. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 2012;122: 143-59.
24. Imagawa T, Yokota S, Mori M, Miyamae T, Takei S, Imanaka H, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol 2012;22: 109-15.
25. Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Nomura S, et al. Interleukin 6 plays a key role in the development of antigeninduced arthritis. Proc Natl Acad Sci U S A 1998;95: 8222-6.
26. Nowell MA, Richards PJ, Horiuchi S, Yamamoto N, Rose-John S, Topley N, et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol 2003;171: 3202-9.
27. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001;14: 705-14.
28. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo [published erratum appears in Nat Med 2010;16:1341]. Nat Med 2000;6: 583-8.
29. McLoughlin RM, Jenkins BJ, Grail D, Williams AS, Fielding CA, Parker CR, et al. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A 2005;102: 9589-94.
30. Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 1994;300: 281-90.
31. Peake NJ, Khawaja K, Myers A, Nowell MA, Jones SA, Rowan AD, et al. Interleukin-6 signalling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor. Rheumatology (Oxford) 2006;45: 1485-9.
32. Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF - and IL-17. Rheumatology (Oxford) 2008;47: 1635-40.
33. Kwan Tat S, Padrines M, Theoleyre S, Heymann D, Fortun Y. IL-6, RANKL, TNF-/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004;15: 49-60.
34. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998;152: 943-51.
35. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2012;51 Suppl 5:v3-11.
36. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003;32: 1-7.
37. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000;1: 510-4.
38. Bode JG, Nimmesgern A, Schmitz J, Schaper F, Schmitt M, Frisch W, et al. LPS and TNF- induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages. FEBS Lett 1999;463: 365-70.
39. Korb A, Tohidast-Akrad M, Cetin E, Axmann R, Smolen J, Schett G. Differential tissue expression and activation of p38 MAPK -, -, -, and - isoforms in rheumatoid arthritis. Arthritis Rheum 2006; 54: 2745-56.
40. Dittrich E, Rose-John S, Gerhartz C, Mullberg J, Stoyan T, Yasukawa K, et al. Identification of a region within the cytoplasmic domain of the interleukin-6 (IL-6) signal transducer gp130 important for ligand-induced endocytosis of the IL-6 receptor. J Biol Chem 1994;269: 19014-20.
41. Hidalgo E, Essex SJ, Yeo L, Curnow SJ, Filer A, Cooper MS, et al. The response of T cells to interleukin-6 is differentially regulated by the microenvironment of the rheumatoid synovial fluid and tissue. Arthritis Rheum 2011;63: 3284-93.
42. Dunne A, O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003;2003:re3.
43. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin- 6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994;83: 113-8.